Type II innate lymphoid cell plasticity contributes to impaired reconstitution after allogeneic hematopoietic stem cell transplantation
- PMID: 39019846
- PMCID: PMC11255294
- DOI: 10.1038/s41467-024-50263-7
Type II innate lymphoid cell plasticity contributes to impaired reconstitution after allogeneic hematopoietic stem cell transplantation
Abstract
Type II innate lymphoid cells (ILC2s) maintain homeostasis and barrier integrity in mucosal tissues. In both mice and humans, ILC2s poorly reconstitute after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Determining the mechanisms involved in their impaired reconstitution could improve transplant outcomes. By integrating single-cell chromatin and transcriptomic analyses of transplanted ILC2s, we identify a previously unreported population of converted ILC1-like cells in the mouse small intestine post-transplant. Exposure of ILC2s to proinflammatory cytokines resulted in a mixed ILC1-ILC2 phenotype but was able to convert only a small population of ILC2s to ILC1s, which were found post-transplant. Whereas ILC2s protected against acute graft-versus-host disease (aGVHD) mediated mortality, infusion of proinflammatory cytokine-exposed ILC2s accelerated aGvHD. Interestingly, murine ILC2 reconstitution post-HSCT is decreased in the presence of alloreactive T cells. Finally, peripheral blood cells from human patients with aGvHD have an altered ILC2-associated chromatin landscape compared to transplanted controls. These data demonstrate that following transplantation ILC2s convert to a pro-pathogenic population with an ILC1-like chromatin state and provide insights into the contribution of ILC plasticity to the impaired reconstitution of ILC2 cells, which is one of several potential mechanisms for the poor reconstitution of these important cells after allo-HSCT.
© 2024. The Author(s).
Conflict of interest statement
J.S.S. has received research funding from Merck Inc., Carisma Therapeutics, and Glaxo Smith Kline and is a compensated consultant for PIQUE Therapeutics. J.S.S./D.B. Intellectual Property: 16,598,914, D.B./J.S.S.: US patent 11,471,517. S.G.P. and I.J.D. own equity in Triangle Biotechnology, Inc. S.G.P. is an inventor of Intellectual Property related to this research that is licensed to Triangle Biotechnology, Inc. from the University of North Carolina at Chapel Hill. The remaining authors declare no competing interests.
Figures
References
MeSH terms
Substances
Grants and funding
- R01GM138912/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
- R01CA276663/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- P30 DK034987/DK/NIDDK NIH HHS/United States
- 1R01HL139730-03/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- T32 CA211056/CA/NCI NIH HHS/United States
- R01 CA276663/CA/NCI NIH HHS/United States
- 1T32CA211056-01A1/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- P30 AI050410/AI/NIAID NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- T32GM067553/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
- 1R01HL155098-01A1/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- T32 GM067553/GM/NIGMS NIH HHS/United States
- T32 CA196589/CA/NCI NIH HHS/United States
- R01 GM138912/GM/NIGMS NIH HHS/United States
- P30 CA016086/CA/NCI NIH HHS/United States
- R01 HL155098/HL/NHLBI NIH HHS/United States
- K12 GM000678/GM/NIGMS NIH HHS/United States
- R01 HL139730/HL/NHLBI NIH HHS/United States
- 1K12GM000678-20/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
